Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M300Revenue $M63.4Net Margin (%)-44.0Altman Z-Score-2.4
Enterprise Value $M211EPS $-0.2Operating Margin %-32.8Piotroski F-Score5
P/E(ttm)--Beneish M-Score11.6Pre-tax Margin (%)-44.0Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-26.9Quick Ratio5.0Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %-23.2Current Ratio5.2Lower Leverage y-yY
Price/Free Cash Flow5.7y-y EBITDA Growth Rate %--ROA % (ttm)-15.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-291.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M125ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
$ 2.53-33%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
$ 2.53-19%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
$ 2.53-49%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
$ 2.53-55%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
$ 2.53-61%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
$ 2.53-67%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
$ 2.53-68%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
$ 2.53-21%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-55.46view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-57.83view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-56.6view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-54.66view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-54.58view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.47-43.4view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.78-47.07view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.69-46.06view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-67.56view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-66.49view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
SPECULATIVE Oct 07 2015 
SPECULATIVE Oct 07 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
Trending Now: OREX Oct 11 2015
After-Hours Moves Led By Orexigen Therapeutics, EMC, Clean Energy Fuels And Cadiz Oct 09 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 05 2015
Orexigen Therapeutics, Inc. Earnings Q2, 2015 Oct 01 2015
Orexigen Announces Submission of Contrave® New Drug Application in South Korea Oct 01 2015
Orexigen Announces Submission of Contrave® New Drug Application in South Korea Oct 01 2015
5 Sell-Ranked Biotechs That Fell More Than 5% Today Sep 25 2015
Orexigen Receives $22M Milestone Payment for Contrave Sep 24 2015
Orexigen Therapeutics Receives $15 Million Milestone Payment Sep 23 2015
Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners Sep 23 2015
Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners Sep 23 2015
5 Healthcare Stocks Under $10 Ready To Pop Sep 16 2015
You Should Follow Hedge Funds Into One Semiconductor and One Healthcare Stock Sep 10 2015
Orexigen Therapeutics (OREX) Stock Climbs on $60 Million Investment Sep 10 2015
Mid-Morning Market Update: Markets Mostly Flat; Krispy Kreme Misses Q2 Estimates Sep 10 2015
Orexigen Raises $60 Million in Sale of Common Stock to Baupost Sep 10 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)